Xenon (XP0) Q3 2026 Earnings Report

The call was strongly positive, driven by the submission of the AZK NDA, strong pivotal focal-seizure efficacy, more than 1,500 patient-years of safety exposure, substantial commercial-launch preparation, positive Phase I data for two pain programs, accelerated X-NOVA2 timing and a $1.2 billion cash balance expected to fund operations into 2029. The main challenges were the voluntary pause in new psychiatry enrollment following neuropsychiatric adverse events, the need to establish the psychiatry benefit-risk profile, the time required for broad payer coverage and one qualified syncope event in the XEN1701 study.

Xenon expects to announce top line X-NOVA2 data in December 2026 instead of Q1 2027; the study randomized approximately 360 patients and is well-powered at 90% to demonstrate an approximately 2.5-point placebo-corrected difference on the HAM-D17 at week 6. The company plans to initiate the Phase IIIb/IV X-FIRST study in Q1 2027, expects to initiate Phase II proof-of-concept studies for XEN1701 and XEN1120 in acute pain in the first half of 2027, expects data from NBI-921355 in 2027, and expects cash, cash equivalents, and marketable securities of $1.2 billion to fund operations into 2029; over the next few months, it expects acceptance of its NDA submission, multiple new AZK presentations at AES, top line X-NOVA2 data in MDD, and progression of its pain programs to Phase II proof-of-concept studies.